September 2016 Newsletter

September 27, 2016:

Weak Refractive Market in Q2-2016 Weighs on Ophthalmic Procedure Volume

IOL surgery growth was slightly above expectations but within historical ranges.

September 27, 2016:

Aussies’ Anti-VEGF Success, SMILE Surgery Highlighted at EURETINA, ESCRS Meetings

The overlapping conferences drew an estimated 12 thousand attendees.

September 27, 2016:

J&J Agrees to Acquire Abbott Medical Optics in Cash Deal Worth $4.33 Billion

The transaction is expected to close in the first quarter of 2017.

September 27, 2016:

FDA Approves SMILE Procedure Using Carl Zeiss Meditec’s VisuMax Femtosecond Laser

More than a half a million procedures have been performed since SMILE’s introduction in 2011.

September 27, 2016:

Allergan Acquires RetroSense, Developer of Gene Therapy for Retinal Disease

The deal calls for $60 million up front, plus milestone payments.

September 27, 2016:

AAO Meeting Returns to Chicago’s McCormick Place in Mid-October

The 2016 conference will be held in conjunction with the Asia-Pacific Academy of Ophthalmology.

September 27, 2016:

Countdown to 2016 AAO Meeting: What We Expect in Chicago

Recent FDA approval of Abbott’s Symfony IOL, Zeiss’ SMILE procedure, and Shire’s Xiidra should increase the attention on these products.

September 27, 2016:

Market Scope’s Must-See Sessions at the 2016 AAO Meeting

September 27, 2016:

Market Scope to Exhibit at 2016 AAO Meeting

We will be located in Booth 2451 in Chicago.

September 27, 2016:

EURETINA Covers the Gamut from Disease Management to New Technology

Presenters reported similar outcomes for Europe’s three approved retinal prostheses; LUMINOUS study data revealed extraordinary outcomes for anti-VEGF treatment in Australia.

September 27, 2016:

EURETINA: Ophthalmologists Link Toxic Perfluorocarbon Liquids to 117 Cases of Vision Loss in Spain

The Spanish government ordered a PFC supplier in Germany to withdraw its product from the market.

September 27, 2016:

ESCRS Examines Growing Options for Presbyopia-Correcting IOLs

Extended depth of focus (EDOF) IOL designs and early clinical experience dominated the sessions.

September 27, 2016:

2016 Ophthalmology Futures Forum Highlights Opportunities in Market

A “Shark Tank” session allowed three brave entrepreneurs to pitch their new products.

September 27, 2016:

International Society of Presbyopia Debates Science of Accommodation

Roughly 145 attended this year’s meeting, with visual scientists, leading clinicians, entrepreneurs, and corporate business development staff.

September 27, 2016:

US Health Officials Increase Reporting Requirements for Human Clinical Trials

Rules would take effect in January 2017; researchers will have 90 days to comply.

September 27, 2016:

Market Report: Increased Surgery Volume Will Fuel Growth in Single-Use Ophthalmic Surgical Device Market

The segment is expected to grow at a rate of 4.2 percent through 2021.

September 27, 2016:

Market Report: Global Demand for Refractive Surgery Growing as Economic Conditions Improve, Myopia Rises

Procedures are expected to increase at a rate of 5.5 percent over the next five years.

September 27, 2016:

Andrew Chang to Lead Global Sales of Ophthalmic Devices for Carl Zeiss Meditec

In previous role, Chang was general manager and senior vice president for Bausch + Lomb Surgical.

September 27, 2016:

Valeant Appoints Zoetis’ Paul Herendeen CFO

He replaces Robert Rosiello, who will remain with the Canadian drugmaker.

September 27, 2016:

Allergan CEO Saunders Pledges ‘Responsible Pricing’ for Drug Products

He argues that public resentment of excessive price hikes could undermine innovation within the industry.

September 27, 2016:

Imprimis Proposes Using Compounding to ‘Burst Drug Pricing Bubble’

in a 75-page document, CEO Mark Baum outlines his solution to the US drug pricing crisis.

September 27, 2016:

Presbia Acquires Neoptics’ Patent Portfolio, Secures Protection for Flexivue Microlens

Company expects to file final PMA module in Q4-2017.

September 27, 2016:

FDA Sets Medical Device User Fees, Shortens Approval Timetable in Tentative Proposal

Goal is to reduce the approval timetable to 108 days for 510(k)s and 290 days for PMAs by 2022.

September 27, 2016:

September 2016 News Briefs

Social media